Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human umbilical cord mesenchymal stem cells (hUC-MSCs) developed by Southwest Hospital in China are an investigational cell therapy for the treatment of moderate to severe knee osteoarthritis. These multipotent stem cells are administered via intra-articular injection into the joint cavity. The therapeutic mechanism involves the secretion of various bioactive molecules (paracrine signaling) that modulate the local inflammatory environment, inhibit synovial inflammation, and stimulate the repair and regeneration of damaged articular cartilage. The primary clinical goals are to reduce joint pain, improve physical function, and potentially reverse cartilage loss associated with degenerative joint disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells (Southwest Hospital).